TSW
ZYNE

Thompson Siegel & Walmsley’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Thompson Siegel & Walmsley’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-19,300
Closed -$157K – 786
2018
Q3 		$157K Buy
+19,300
New +$148K ﹤0.01% 416

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Campbell Capital Management Miami, Florida $279M AUM 49.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thompson Siegel & Walmsley's ZYNE Position: Q4 2018 in Review

Thompson Siegel & Walmsley sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2018, closing a stake of 19,300 shares — an estimated $157K sold.

Thompson Siegel & Walmsley first reported a position in ZYNE in Q3 2018 and held it in 1 quarter. The position peaked at $157K in Q3 2018. 62 funds tracked by Wall St. Rank hold ZYNE as of Q4 2018.

  • Thompson Siegel & Walmsley reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2018 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 19,300 Zynerba Pharmaceuticals, Inc shares in Q4 2018, an estimated $157K.
  • Thompson Siegel & Walmsley first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2018 and held it in 1 quarter.
  • Thompson Siegel & Walmsley's Zynerba Pharmaceuticals, Inc position peaked at $157K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2018.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2018, filed 11 Feb 2019.